Share: 
Menactra® (meningococcal vaccine) is used to provide protection against invasive meningococcal disease caused by the Neisseria meningitidis bacteria. It is approved for use in individuals 9 months through 55 years of age. Invasive meningococcal diseases include:
- Bacterial meningitis (a bacterial infection of the fluid surrounding the brain and spinal cord)
- Bloodstream infections.
(Click Menactra Uses for more information on what the vaccine is used for, including possible off-label uses.)
Menactra does not contain thimerosal, a mercury-containing preservative. People who are concerned about exposure to this substance can be confident that this vaccine has no thimerosal -- not even trace amounts. Some people also are concerned about the aluminum content of vaccines. This vaccine contains no aluminum.
Menactra is not made from animal components or human fetal cell lines, unlike some vaccines.
Menactra is made by Sanofi Pasteur, Inc.
Other Articles in This eMedTV Presentation
eMedTV Links
Copyright © 2006-2013 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.
This site complies with the HONcode standard for trustworthy health information:
verify here.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.
This site complies with the HONcode standard for trustworthy health information:
verify here.